Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Abbott Laboratories/Home Access

This article was originally published in The Gray Sheet

Executive Summary

Abbott Laboratories/Home Access: Firms ink exclusive agreement to collaborate on development and marketing of home diagnostic tests employing Home Access' telemedicine test reporting and patient counseling service. Under the terms of the deal, Abbott will market tests to be developed by Home Access, which is responsible for gaining FDA approval and for providing related test result counseling services. Financial terms were not disclosed. Hoffman Estates, Illinois-based Home Access says that it is conducting research in the areas of genetics, cancer, drug testing, reproductive health and nutrition. The firm is currently the only company marketing FDA-approved at-home diagnostic tests with counseling services (telemedicine) -- the Home Access and Home Access Express HIV test systems. The firm notes that the home diagnostic tests under development likely will function along the same lines as the Home Access HIV test systems, which allow people to obtain the test sample at home and anonymously obtain the results by phone...

You may also be interested in...

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

More Surufatinib Cheer For Chi-Med As Second NET Trial Stopped Early

Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts